- Home
- SYBX
SYBX
Synlogic Inc.
as of 12-23-2025 12:39pm EST
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | WINCHESTER |
| Market Cap: | 15.2M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 77.3K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.26 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.90 - $1.96 | Next Earning Date: | 11-13-2025 |
| Revenue: | N/A | Revenue Growth: | -99.76% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Synlogic Inc. (SYBX)
See Remarks below
Avg Cost/Share
$1.81
Shares
157
Total Value
$284.17
Owned After
12,744
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Dooley Mary Beth | SYBX | See Remarks below | Oct 29, 2025 | Sell | $1.81 | 157 | $284.17 | 12,744 |
Compare SYBX vs Leading Stocks
See how SYBX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "SYBX Synlogic Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.